Greg Critchfield: Yes. Okay. I’ll try and answer both, and make sure I get it right. Okay. Tom, just make sure. The — with regard to the readouts and the timeline, what we’re — the guidance that we’re giving to people on those events are this year we will complete the interim look of the PRIME study. Once the PRIME study is fully enrolled and the — that could be at the time of the interim look. Once it is fully enrolled, at that point then, you still have to wait for the babies that are most recently enrolled to be born for the outcomes to be known and for the data clean up analysis activities take place. But it’s several months. We’re not prepared to tell besides at this point in time. But what we can tell you is, we have the 2,800 patients needed for the interim look to take place this year, and it would be later that the final look would be available. Does that make sense?
Tom Stevens: That makes a lot of sense. And then just following up on the reimbursement side, if you get a positive PRIME readout, do you expect insurance to cover all the other interventions required to ensure that you get the impact on NICU mortality that you’re going to test?
Greg Critchfield: You actually answered the question somewhat and I’ll expand on it. The health economics are really important. And what we have demonstrated in multiple health economic analyses is, it is very cost effective and the savings to payers are enormous but — through the implementation of the test-and-treat strategy. By identifying the patients who have higher risk of preterm delivery and then the clinical data are showing by impacting them positively, they spend less time in the NICU, they have fewer complications, the babies are healthier and that pay benefits to the child and mother first, to families, to the medical community and to payers. So we believe that it’s totally aligned with the idea of saving money.
And that also gives you a sense of the amount of savings that is generated, gives you some sense of where pricing makes good — you make good decisions about pricing. And we believe that, that increases the value of the test. So continued positive results are what we are looking for, and we will know when the studies have read out with their final plans. I think we will have a pretty good idea from the interim looks where it should track.
Tom Stevens: Got it. And then just last quick one. So you kind of assume at 250 ASP in ’25, what kind of gross margin should we be expecting on that?
Greg Critchfield: We have not really talked about 250 ASP. For any — we haven’t put anything down like that. Jay?
Jay Moyes: No. We haven’t put any guidance out on ASP or gross margins.
Greg Critchfield: Yes. That’s right.
Tom Stevens: Got it. Yes, I’ll get back to the queue.
Greg Critchfield: Just one of the — we expect it to change. We believe that the ASP gross margins will change, as the volumes get larger, as we get more payers under contract. On all those things we believe will cause changes in them. We can’t quantify the magnitude of them yet, but it’s certain that, they will not stay identical